CD38 and neoplasm: Studies show that daratumumab stimulates stronger induction of Fc-dependent immune effector mechanisms CDC and ADCP as compared to isatuximab; however, isatuximab is unique in its ability to directly induce apoptosis in the cancer cells and inhibit tumor-promoting enzyme-mediated activities of CD38 due to direct binding to its ecto-enzymatic site [89].